Phase Ia Study of a LentiGen® CD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Patients With Relapsed/Refractory CD19 Positive Acute Lymphoblastic Leukemia (ALL) Using a Closed Transduction System
Latest Information Update: 29 Jan 2026
At a glance
- Drugs CD19-CAR-T-cell-therapy-Miltenyi-Biomedicine (Primary)
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- Acronyms CD19 CART CELL
Most Recent Events
- 29 Jan 2026 New trial record